Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:684
Name hepatocellular carcinoma
Definition A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver.
Source DiseaseOntology.org
Alt Ids DOID:5005
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer liver carcinoma hepatocellular carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CTNNB1 mutant PMED-1 hepatocellular carcinoma sensitive detail...
TP53 Y220C CP-31398 hepatocellular carcinoma sensitive detail...
TP53 R249S CP-31398 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos AZD4547 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos PHA-665752 hepatocellular carcinoma no benefit detail...
NRAS mutant Refametinib + Sorafenib hepatocellular carcinoma sensitive detail...
PIK3CA mutant Sorafenib hepatocellular carcinoma decreased response detail...
PTEN mutant Sorafenib hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-L1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody + unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
TP53 Y220C SLMP53-2 hepatocellular carcinoma sensitive detail...
TP53 Y220C SLMP53-2 + Sorafenib hepatocellular carcinoma sensitive detail...
FLT3 over exp Sorafenib hepatocellular carcinoma sensitive detail...
CD274 positive Camrelizumab + Rivoceranib hepatocellular carcinoma not predictive detail...
MLH1 negative Dostarlimab-gxly hepatocellular carcinoma sensitive detail...
MSH2 negative Dostarlimab-gxly hepatocellular carcinoma sensitive detail...
PMS2 negative Dostarlimab-gxly hepatocellular carcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly hepatocellular carcinoma sensitive detail...
CTNNB1 G34R Everolimus + Sorafenib hepatocellular carcinoma predicted - sensitive detail...
RET fusion Selpercatinib hepatocellular carcinoma sensitive detail...
CTNNB1 S37C WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 G34V WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 T41A WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 S33F WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 S37F CTNNB1 S45Y WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 S45F WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 S45P WNTinib hepatocellular carcinoma sensitive detail...
CTNNB1 mutant WNTinib hepatocellular carcinoma predicted - sensitive detail...
CTNNB1 mut KIT V559D KIT T670I WNTinib hepatocellular carcinoma predicted - sensitive detail...
CTNNB1 mut MAP2K1 S218D MAP2K1 S222D WNTinib hepatocellular carcinoma predicted - resistant detail...
BRAF T529N CTNNB1 mut WNTinib hepatocellular carcinoma predicted - sensitive detail...
CTNNB1 act mut WNTinib hepatocellular carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00986661 Phase I PV-10 A Study to Assess PV-10 Chemoablation of Cancer of the Liver Active, not recruiting USA 0
NCT01015833 Phase III Doxorubicin Sorafenib Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed USA | CAN 1
NCT01075113 Phase I Sorafenib + Vorinostat Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT01141478 Phase I Sorafenib Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria Terminated USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01246986 Phase II Galunisertib + Sorafenib Galunisertib A Study of LY2157299 in Participants With Hepatocellular Carcinoma Completed USA | ITA | FRA | ESP | DEU | AUS 1
NCT01306058 Phase Ib/II Carotuximab + Sorafenib Sorafenib and TRC105 in Hepatocellular Cancer Completed USA 0
NCT01356628 Phase II Palbociclib A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Active, not recruiting USA 0
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Completed USA | ITA | FRA | ESP | BEL 0
NCT01556490 Phase III Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT01567930 Phase II Temsirolimus Temsirolimus as Second-line Therapy in HCC Unknown status USA 0
NCT01624285 Phase II Sorafenib Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer Completed USA 0
NCT01628640 Phase I VSV-IFN-beta Viral Therapy in Treating Patient With Liver Cancer Active, not recruiting USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT01655693 Phase III Doxorubicin Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 4
NCT01658878 Phase I Nivolumab Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 6
NCT01666756 Phase I Sorafenib + YIV-906 Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT01687673 Phase II Sorafenib + Temsirolimus Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Completed USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DEU 1
NCT01730937 Phase III Sorafenib Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Active, not recruiting USA | CAN | AUS 2
NCT01754987 Phase Ib/II Sorafenib A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Completed USA 0
NCT01755767 Phase III Tivantinib Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 7
NCT01761266 Phase III Lenvatinib Sorafenib A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT01774344 Phase III Regorafenib Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 12
NCT01775501 Phase II Sorafenib Fluorouracil Oxaliplatin Leucovorin Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed USA 0
NCT01801163 Phase I Sorafenib A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) Withdrawn USA 0
NCT01835223 Phase Ib/II Tivozanib Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT01840592 Phase II Doxorubicin + Sorafenib Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib Active, not recruiting USA 0
NCT01849588 FDA approved Sorafenib Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Terminated USA 0
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed USA 0
NCT01887717 Phase III Sorafenib Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein Terminated USA | ITA | GBR | FRA | ESP | BEL 0
NCT01900002 Phase II Sorafenib Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT01908426 Phase III Cabozantinib Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT01915602 Phase II Refametinib + Sorafenib Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 13
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | AUS 1
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 6
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT02024087 Phase Ib/II Dalantercept + Sorafenib Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02069145 Phase I Ipafricept + Sorafenib Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Completed USA 0
NCT02072486 Phase I Sorafenib Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed USA 0
NCT02101593 Phase I ADI-PEG 20 Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer Completed USA 0
NCT02128958 Phase II CF102 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Completed USA 4
NCT02143401 Phase I Navitoclax + Sorafenib Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Active, not recruiting USA 0
NCT02151864 Phase I Sonidegib LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis Completed USA 0
NCT02174549 Phase I Tirapazamine Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Active, not recruiting USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02227914 Phase Ib/II Oprozomib Sorafenib Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Withdrawn USA 0
NCT02232633 Phase II Amcasertib A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Completed CAN 0
NCT02279719 Phase Ib/II Sorafenib Amcasertib + Sorafenib Napabucasin + Sorafenib A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Completed USA 0
NCT02288507 Phase I Sorafenib Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Withdrawn USA 0
NCT02292173 Phase I Sorafenib + Trametinib Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer Completed USA 0
NCT02314052 Phase Ib/II DCR-MYC Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma Terminated USA 2
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA | FRA 2
NCT02323906 Phase Ib/II CC-122 + Sorafenib Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer Terminated USA 0
NCT02406508 Phase II Melphalan Sorafenib Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Withdrawn USA 0
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA | ESP 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02435433 Phase III Ramucirumab A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT02460991 Phase I Sorafenib Doxorubicin A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Terminated USA 0
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 6
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | ESP | DEU | BEL | AUT | AUS 3
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Active, not recruiting USA | ITA | ESP 6
NCT02524119 Phase II Ribociclib LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) Terminated USA 0
NCT02528643 Phase II Enzalutamide A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Completed USA | ITA | GBR | ESP | CAN 4
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02560779 Phase Ib/II Carotuximab + Sorafenib Trial of TRC105 and Sorafenib in Patients With HCC Completed USA 0
NCT02562755 Phase III JX-594 Sorafenib Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed USA | ITA | GBR | FRA | DEU | CAN | AUS 9
NCT02564614 Phase I EZN-2968 A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) Completed USA 0
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Completed USA | ITA | FRA | ESP | DEU 3
NCT02575339 Phase Ib/II Sorafenib Sapanisertib MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Terminated USA 0
NCT02576509 Phase III Nivolumab Sorafenib A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02642913 Phase Ib/II Enzalutamide Sorafenib Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Completed USA 0
NCT02658019 Phase II Pembrolizumab Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Completed USA 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT02702401 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Completed 0
NCT02702414 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Completed 0
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Completed USA | AUS 5
NCT02795429 Phase Ib/II Spartalizumab Capmatinib + Spartalizumab Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Completed ITA | FRA | DEU | CAN 4
NCT02821754 Phase Ib/II Durvalumab + Tremelimumab A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed USA 0
NCT02834780 Phase I H3B-6527 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Completed USA | ITA | GBR | FRA | ESP | CAN | BEL 4
NCT02837029 Phase I Nivolumab Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT02842125 Phase I Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Terminated USA 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02859324 Phase Ib/II CC-122 + Nivolumab A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) Completed USA | ITA | FRA | ESP 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02905188 Phase I GLYCAR T cells Cyclophosphamide + Fludarabine Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) Completed USA 0
NCT02906397 Phase I Galunisertib A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT02939807 Phase II ABC294640 A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma Withdrawn USA 0
NCT02940496 Phase Ib/II Pembrolizumab Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Completed USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CAN | AUT 4
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02988440 Phase I Sorafenib + Spartalizumab Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients Completed USA | ITA | ESP | DEU | CAN 3
NCT02989870 Phase I Bavituximab + Sorafenib Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Withdrawn USA 0
NCT03006926 Phase I Lenvatinib + Pembrolizumab A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma Completed USA | ITA | GBR | FRA | ESP 2
NCT03017326 Phase III Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Paediatric Hepatic International Tumour Trial (PHITT) Recruiting GBR | FRA | ESP | DEU | BEL | AUT 7
NCT03037437 Phase II Hydroxychloroquine + Sorafenib Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Recruiting USA 0
NCT03059147 Phase I SF1126 A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma Terminated USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Completed USA 0
NCT03099564 Phase I Pembrolizumab Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Active, not recruiting USA 0
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Active, not recruiting USA | GBR | FRA | ESP 0
NCT03143270 Phase I Nivolumab A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Active, not recruiting USA 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03145558 Phase II Doxorubicin Tirapazamine TATE Versus TACE in Intermediate Stage HCC (TATE) Suspended USA 0
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Terminated USA 0
NCT03211416 Phase Ib/II Pembrolizumab + Sorafenib Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Active, not recruiting USA 0
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Completed USA 0
NCT03253289 Phase I Meclizine Meclizine for Hepatocellular Carcinoma (OPTIM) Active, not recruiting USA 0
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Active, not recruiting USA 0
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Recruiting USA | GBR 0
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 11
NCT03299946 Phase I Cabozantinib + Nivolumab Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT03316222 Phase Ib/II GNS561 Study of GNS561 in Patients With Liver Cancer Terminated USA | FRA | BEL 0
NCT03316872 Phase II Pembrolizumab Study of Pembrolizumab and Radiotherapy in Liver Cancer Recruiting CAN 0
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated USA 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Completed USA 0
NCT03347292 Phase I Pembrolizumab + Regorafenib Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC Completed USA | DEU 0
NCT03382886 Phase I Bevacizumab + Nivolumab Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE) Terminated USA 0
NCT03383458 Phase III Nivolumab A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT03412773 Phase III Tislelizumab Sorafenib Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC Completed USA | ITA | GBR | FRA | ESP | DEU 5
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Completed USA 0
NCT03419897 Phase II Tislelizumab Study of BGB-A317 in Patients With Previously Treated Unresectable HCC Completed ITA | GBR | FRA | ESP | DEU 3
NCT03433703 Phase II Lenvatinib Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) Terminated USA 0
NCT03434379 Phase III Atezolizumab + Bevacizumab Sorafenib A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03439891 Phase II Nivolumab + Sorafenib Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Active, not recruiting USA 0
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Completed USA | DEU 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03482102 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Recruiting USA 0
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Terminated USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03519997 Phase II Bavituximab + Pembrolizumab A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA 0
NCT03533582 Phase II Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Active, not recruiting USA | CAN | AUS 3
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Active, not recruiting USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03563170 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib Sorafenib QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Withdrawn USA 0
NCT03582618 Phase II CVM-1118 + Sorafenib CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma Terminated USA 1
NCT03630640 Phase II Nivolumab Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) Active, not recruiting FRA 0
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Terminated USA | ITA | ESP | CAN | BEL 3
NCT03638141 Phase II Durvalumab + Tremelimumab CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Active, not recruiting USA 0
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting USA 0
NCT03655002 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer Active, not recruiting USA 0
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Active, not recruiting USA | ITA | GBR | FRA | ESP 7
NCT03665129 Phase I Avdoralimab + Durvalumab IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Terminated USA | FRA 0
NCT03680508 Phase II Cobolimab + Dostarlimab-gxly TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer Recruiting USA 0
NCT03682276 Phase Ib/II Ipilimumab + Nivolumab Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC) Recruiting GBR 0
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed USA | GBR | FRA | ESP | AUS 1
NCT03695250 Phase Ib/II Linrodostat + Nivolumab BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer Terminated USA 0
NCT03713593 Phase III Lenvatinib Lenvatinib + Pembrolizumab Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | GBR | FRA | ESP 2
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03753659 Phase II Pembrolizumab IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Active, not recruiting DEU 0
NCT03755791 Phase III Cabozantinib Sorafenib Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 24
NCT03778957 Phase III Durvalumab Bevacizumab + Durvalumab A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 12
NCT03781934 Phase Ib/II MIV-818 A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Active, not recruiting GBR | ESP | BEL 1
NCT03781960 Phase II Abemaciclib + Nivolumab Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma Terminated USA 0
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Completed USA 0
NCT03812562 Phase I Nivolumab Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection Terminated USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | CAN | BEL | AUS 5
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Active, not recruiting USA | ITA | GBR 3
NCT03836352 Phase II Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting USA | CAN 0
NCT03847428 Phase III Durvalumab Bevacizumab + Durvalumab Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) Active, not recruiting USA | ITA | FRA | DEU | CAN | AUT | AUS 17
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03867084 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT03897543 Phase Ib/II ABX196 + Nivolumab ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Unknown status USA 0
NCT03908840 Phase I TBI-302 Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma Unknown status USA 0
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03937830 Phase II Bevacizumab + Doxorubicin + Durvalumab Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma Recruiting USA 0
NCT03942328 Phase II Atezolizumab + Bevacizumab + PCV13 vaccine PCV13 vaccine Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Recruiting USA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT03970616 Phase Ib/II Durvalumab + Tivozanib A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma Terminated USA 0
NCT03993873 Phase Ib/II TPX-0022 Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) Active, not recruiting USA | FRA | ESP 2
NCT03998033 Phase Ib/II ET140202 Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Terminated USA 0
NCT04008797 Phase I Lenvatinib E7386 + Lenvatinib A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor Recruiting USA | FRA 3
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0
NCT04039607 Phase III Lenvatinib Sorafenib Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT04050462 Phase II BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients Active, not recruiting USA 0
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU 1
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04102098 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04123379 Phase II BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Active, not recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04134559 Phase II Pembrolizumab Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma Recruiting USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn USA | FRA | ESP 0
NCT04170556 Phase Ib/II Nivolumab + Regorafenib Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING) Active, not recruiting ESP 0
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Active, not recruiting USA 0
NCT04194775 Phase III CS1003 + Lenvatinib Lenvatinib A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma Active, not recruiting USA | ITA | ESP 3
NCT04204850 Phase II Cabozantinib Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx) Recruiting CAN 0
NCT04246177 Phase III Lenvatinib + Pembrolizumab Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 20
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04268888 Phase II Nivolumab Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3) Recruiting GBR 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04291105 Phase II Cemiplimab + VSV-hIFNbeta-NIS Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Recruiting USA 1
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Terminated USA | ITA 1
NCT04316182 Phase II Cabozantinib Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) (ACTION) Completed ESP 0
NCT04327700 Phase II Regorafenib Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib Suspended USA 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04340193 Phase III Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT04358185 Phase I Itacitinib Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL) Active, not recruiting GBR 0
NCT04374877 Phase I SRF388 Study of SRF388 in Patients With Advanced Solid Tumors Recruiting USA 2
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04430452 Phase II Durvalumab Durvalumab + Tremelimumab Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition Recruiting USA 0
NCT04435977 Phase II Cabozantinib Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma (Immunocabo) Unknown status ITA 0
NCT04442581 Phase II Cabozantinib + Pembrolizumab Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer Terminated USA 0
NCT04454762 Phase II Cabozantinib A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function (CaboCHILD) Unknown status DEU 0
NCT04472767 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma Recruiting USA 0
NCT04476329 Phase II Regorafenib Optimization for Regorafenib in HCC (ReDos HCC) Terminated USA 0
NCT04487067 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA) Active, not recruiting ITA 0
NCT04497038 Phase Ib/II Cabozantinib Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy Active, not recruiting USA 0
NCT04502082 Phase Ib/II ET140203 Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET121) Recruiting USA 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Completed USA 0
NCT04511455 Phase II Cabozantinib A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment Recruiting DEU 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Completed USA | ITA | FRA | ESP | DEU | CAN 8
NCT04522544 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design Recruiting DEU 0
NCT04522908 Phase II Cabozantinib Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis Active, not recruiting DEU 0
NCT04524871 Phase Ib/II Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) Recruiting USA | FRA 5
NCT04541173 Phase II Atezolizumab + Bevacizumab Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Terminated USA 0
NCT04563338 Phase II Atezolizumab Atezolizumab + Bevacizumab An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) Recruiting CAN 0
NCT04567615 Phase II Nivolumab Nivolumab + Relatlimab A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors Active, not recruiting FRA | ESP 15
NCT04605731 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Recruiting USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Recruiting USA | GBR | CAN 1
NCT04634357 Phase Ib/II ET140203 ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) Recruiting USA 0
NCT04658147 Phase I Nivolumab + Relatlimab Nivolumab Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04676633 Phase I Cotsiranib Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Active, not recruiting USA 1
NCT04678908 Phase I HB0025 A Study of Injection HB0025 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04696055 Phase II Pembrolizumab + Regorafenib Pilot Study of Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors Active, not recruiting USA | ITA | FRA | ESP | DEU 3
NCT04710641 Phase II CEBPA-51 + Sorafenib Sorafenib Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2) Active, not recruiting USA 1
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04721132 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Recruiting USA 0
NCT04727307 Phase II Atezolizumab + Bevacizumab Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02) Recruiting FRA 0
NCT04732286 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy Active, not recruiting ESP 0
NCT04740307 Phase II Lenvatinib + MK-1308A Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) Active, not recruiting USA | ITA | ESP 6
NCT04752215 Phase I BI 765049 + Ezabenlimab BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker Recruiting USA | CAN 0
NCT04767906 Phase II Cabozantinib Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture) Recruiting DEU 0
NCT04770896 Phase III Atezolizumab + Lenvatinib Lenvatinib + Sorafenib Atezolizumab + Sorafenib A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251) Recruiting ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 22
NCT04777708 Phase I BO-112 + Pembrolizumab BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Terminated USA 0
NCT04777851 Phase III Pembrolizumab + Regorafenib Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (REPLACE) Recruiting USA | ITA | FRA | ESP | DEU | BEL 7
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Active, not recruiting USA 0
NCT04803994 Phase III Atezolizumab + Bevacizumab The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma Recruiting ESP | DEU | AUT 0
NCT04823403 Phase I Ipilimumab + Nivolumab Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV) Recruiting FRA 0
NCT04828486 Phase II Futibatinib + Pembrolizumab Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Recruiting USA 0
NCT04829383 Phase II Atezolizumab + Bevacizumab A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) Active, not recruiting USA 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04857684 Phase I Atezolizumab + Bevacizumab SBRT + Atezolizumab + Bevacizumab in Resectable HCC Recruiting USA 0
NCT04864054 Phase Ib/II ECT204 T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3) Recruiting USA 0
NCT04878484 Phase I TCRT-ESO-A2 Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors Withdrawn 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Recruiting USA | CAN | BEL 4
NCT04965714 Phase II ADI-PEG 20 + Nivolumab Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer Withdrawn USA 0
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | FRA | ESP | BEL | AUS 5
NCT04989387 Phase I INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 Study of INCA 0186 in Subjects With Advanced Solid Tumors Active, not recruiting USA | GBR | ESP | BEL | AUT 1
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT05027425 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant Recruiting USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05039736 Phase II Cabozantinib + Nivolumab A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy Withdrawn 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05063565 Phase II Durvalumab + Tremelimumab + Yttrium-90 microsphere therapy TheraSphere With and Without Durvalumab and Tremelimumab for HCC (ROWAN) Recruiting USA | FRA | ESP 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05091346 Phase Ib/II E7386 + Pembrolizumab A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Recruiting USA | GBR | FRA | ESP 1
NCT05092373 Phase I Cabozantinib Atezolizumab + Nab-paclitaxel Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting USA 0
NCT05093608 Phase I Atezolizumab + Bevacizumab + Selinexor SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma Terminated USA 0
NCT05096715 Phase I Atezolizumab + Bevacizumab Atezolizumab+Bevacizumab+SBRT in Unresectable HCC Not yet recruiting USA 0
NCT05101629 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy Active, not recruiting DEU 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05103904 Phase II Lenvatinib Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Recruiting USA 0
NCT05104567 Phase II Cetuximab + THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05109052 Phase Ib/II Atezolizumab + Bevacizumab + PXS-5505 Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma Withdrawn USA 0
NCT05109442 Phase Ib/II AFM24 + Atezolizumab Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers Recruiting USA | GBR | ESP 2
NCT05113186 Phase II Lenvatinib Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (LENVABLA) Recruiting FRA 0
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05120271 Phase Ib/II BOXR1030 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) Recruiting USA 0
NCT05168163 Phase II Atezolizumab + Cabozantinib Cabozantinib Atezolizumab + Lenvatinib Lenvatinib Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Recruiting USA 0
NCT05171335 Phase II Lenvatinib Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients Enrolling by invitation USA 0
NCT05176665 Phase Ib/II EMB-01 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Recruiting USA 1
NCT05178043 Phase II Ascrinvacumab + Nivolumab GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA 0
NCT05185505 FDA approved Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria Recruiting USA 0
NCT05185739 Phase II Lenvatinib + Pembrolizumab Lenvatinib Pembrolizumab Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1) Recruiting GBR 0
NCT05194293 Phase II Durvalumab + Regorafenib Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Recruiting USA 0
NCT05201404 Phase III CF102 Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis (LIVERATION) Recruiting USA 8
NCT05211323 Phase II Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer Recruiting USA 0
NCT05212922 Phase II Toripalimab-tpzi + YH001 A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) Withdrawn AUT | AUS 3
NCT05220722 Phase Ib/II Pembrolizumab + SD-101 Ipilimumab + Nivolumab + SD-101 Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors Active, not recruiting USA 0
NCT05223816 Phase II Nivolumab + VG161 VG161 An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT05228015 Phase I IK-930 Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05229601 Phase I HFB301001 A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05249426 Phase I Cetuximab + Effi-DEM + Ezabenlimab BI 836880 + Effi-DEM + Ezabenlimab Effi-DEM + Ezabenlimab A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer Recruiting USA | ITA | GBR | FRA | ESP 7
NCT05249569 Phase II Avelumab + Axitinib + Bavituximab Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Terminated USA 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05293496 Phase I MGC018 + MGD019 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT05301842 Phase III Durvalumab + Lenvatinib + Tremelimumab Durvalumab + Tremelimumab Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 16
NCT05327738 Phase II Atezolizumab + Cabozantinib + Yttrium-90 microsphere therapy Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Withdrawn 0
NCT05337137 Phase Ib/II Bevacizumab + Nivolumab + Relatlimab Bevacizumab + Nivolumab A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 8
NCT05345678 Expanded access Durvalumab + Tremelimumab Himalaya Early Access Program Approved for marketing USA 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05359861 Phase II Atezolizumab + Bevacizumab + SRF388 Atezolizumab + Bevacizumab Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma Active, not recruiting USA | AUS 2
NCT05366829 Phase II Tislelizumab Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma Recruiting USA 0
NCT05417321 Phase Ib/II HB0036 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT05438420 Phase Ib/II Pembrolizumab + Q702 Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Recruiting USA 1
NCT05440708 Phase Ib/II Atezolizumab + Bevacizumab + C188-9 C188-9 C188-9 + Pembrolizumab A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Recruiting USA 0
NCT05440864 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) Recruiting ITA | ESP | CAN 0
NCT05448677 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + GNS561 Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER) Recruiting FRA 0
NCT05450562 Phase Ib/II Atezolizumab + SAR444200 SAR444200 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors Recruiting USA | CAN 3
NCT05451043 Phase II Cisplatin + Durvalumab + Gemcitabine + Propranolol + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Propranolol + Tremelimumab Durvalumab + Propranolol + Tremelimumab Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) Not yet recruiting CAN 0
NCT05468359 Phase Ib/II Atezolizumab + Bevacizumab + Cyclophosphamide + Sorafenib Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Recruiting USA 0
NCT05482516 Phase III Atezolizumab + Bevacizumab Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) Recruiting USA 0
NCT05488522 Phase I Atezolizumab + Bevacizumab SBRT With Atezo/Bev for HCC Recruiting USA 0
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05497453 Phase Ib/II OTX-2002 A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) Recruiting USA 4
NCT05528952 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + UCPVax Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO) Recruiting FRA 0
NCT05537402 Phase II Atezolizumab + Bevacizumab LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial (LOST-B) Recruiting USA 0
NCT05546879 Phase I Atezolizumab + Bevacizumab + NP137 Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma (Liver-NET1) Recruiting FRA 0
NCT05584670 Phase Ib/II SAR445877 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Recruiting USA | ESP 2
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05620771 Phase II Yttrium-90 microsphere therapy Atezolizumab + Bevacizumab Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk Recruiting USA 0
NCT05622071 Phase II Tislelizumab Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA) Recruiting FRA 0
NCT05630937 Phase Ib/II NMS-01940153E Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy Active, not recruiting USA | ITA | ESP 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05665348 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Ipilimumab Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) Not yet recruiting FRA 0
NCT05690048 Phase II Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Fecal microbiota + Vancomycin Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA) Not yet recruiting DEU 0
NCT05701488 Phase I Durvalumab + Tremelimumab SIRT With Tremelimumab and Durvalumab for Resectable HCC Recruiting USA 0
NCT05717400 FDA approved Atezolizumab + Bevacizumab Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05724563 Phase II AB154 + Zimberelimab Domvanalimab and Zimberelimab in Advanced Liver Cancers Recruiting USA 0
NCT05733598 Phase II Atezolizumab + Bevacizumab + RP3 RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC Not yet recruiting USA | GBR | FRA | DEU 1
NCT05757492 Phase Ib/II CHS-006 + Toripalimab-tpzi Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05776875 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC Recruiting USA 0
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05797805 Phase Ib/II BC2059 BC2059 + Pembrolizumab A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Recruiting USA | CAN 0
NCT05822752 Phase II Lenvatinib Sorafenib ABBV-151 + Budigalimab Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Recruiting USA | ESP 3
NCT05844046 Phase II Bevacizumab + Durvalumab + Tremelimumab Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC) Recruiting DEU 0
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Recruiting 11
NCT05883644 Phase III Durvalumab + Tremelimumab Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA) Recruiting USA | ITA | FRA | ESP | DEU 5
NCT05901194 Phase Ib/II Lenvatinib Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (Ta-Len-Tra) Not yet recruiting FRA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05904886 Phase III Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 14
NCT05908786 Phase Ib/II Bevacizumab + RO7247669 Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma Recruiting USA | GBR | FRA | ESP 3
NCT05909995 Phase I INCB099280 + Ipilimumab Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Recruiting USA | CAN | AUS 6
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT06006286 Phase Ib/II ADI-PEG 20 + Atezolizumab + Bevacizumab A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma Withdrawn USA 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Recruiting USA 0
NCT06045975 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) Not yet recruiting FRA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06084481 Phase I ABBV-400 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting USA 2
NCT06084884 Phase Ib/II AZD5851 A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA) Recruiting USA 0
NCT06096779 Phase II Atezolizumab + Bevacizumab Atezolizumab A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros) Recruiting USA 0
NCT06108050 Phase I JZP898 + Pembrolizumab JZP898 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06109272 Phase II ABBV-151 + Budigalimab Atezolizumab + Bevacizumab Durvalumab + Tremelimumab A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) Recruiting USA 1
NCT06218511 Phase I Durvalumab + IMA970A + Montanide ISA 51 A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) Recruiting ITA 0
NCT06294548 Phase Ib/II Atezolizumab + Bevacizumab + DS-3201b Phase Ib/II Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC Not yet recruiting USA 0